Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from ... therapy. Analysts at Leerink have suggested the new

  • Ipsen’s liver cancer treatment clears phase III trial Ipsen’s liver cancer treatment clears phase III trial

    Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial ... Data showed cabozantinib provided a ‘statistically

  • NICE gives green light to Ipsen's Cabometyx NICE gives green light to Ipsen's Cabometyx

    To date nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. ... We are delighted that now any eligible patient in the UK can benefit from cabozantinib.

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    For Ipsen, the deal continues its drive to expand its oncology franchise, currently headed by hormonal therapy Somatuline for neuroendocrine tumours and Cabometyx (cabozantinib) for advanced renal cell carcinoma.

  • Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

    The CABOSUN study, presented yesterday at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (cabozantinib) can decrease the rate of disease progression or death by 31% in advanced ... David Meek, Ipsen's chief executive

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... Focusing on the future. In terms of its new oncology products

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.

  • Deal Watch March 2016 Deal Watch March 2016

    marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Quick links

Infographics

Multimedia